GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jeisys Medical Inc (XKRX:287410) » Definitions » EBIT

Jeisys Medical (XKRX:287410) EBIT : ₩38,634 Mil (TTM As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Jeisys Medical EBIT?

Jeisys Medical's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2024 was ₩10,725 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was ₩38,634 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Jeisys Medical's annualized ROC % for the quarter that ended in Jun. 2024 was 30.20%. Jeisys Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 73.19%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Jeisys Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 4.01%.


Jeisys Medical EBIT Historical Data

The historical data trend for Jeisys Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jeisys Medical EBIT Chart

Jeisys Medical Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 71.07 9,195.49 13,481.41 34,277.43 35,720.79

Jeisys Medical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,112.66 10,193.12 8,886.91 8,829.19 10,724.76

Competitive Comparison of Jeisys Medical's EBIT

For the Medical Devices subindustry, Jeisys Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jeisys Medical's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jeisys Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jeisys Medical's EV-to-EBIT falls into.


;
;

Jeisys Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩38,634 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jeisys Medical  (XKRX:287410) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Jeisys Medical's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=41001.924 * ( 1 - 12.01% )/( (108951.089 + 130011.914)/ 2 )
=36077.5929276/119481.5015
=30.20 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=192585.145 - 8111.76 - ( 96582.768 - max(0, 67191.024 - 142713.32+96582.768))
=108951.089

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=204829.396 - 10567.767 - ( 80776.655 - max(0, 64354.593 - 128604.308+80776.655))
=130011.914

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Jeisys Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=42899.036/( ( (34074.566 + max(20839.867, 0)) + (39571.203 + max(22740.664, 0)) )/ 2 )
=42899.036/( ( 54914.433 + 62311.867 )/ 2 )
=42899.036/58613.15
=73.19 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(17407.036 + 24060.295 + 3325.729) - (8111.76 + 0 + 15841.433)
=20839.867

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(14000.095 + 27269.157 + 2727) - (10567.767 + 0 + 10687.821)
=22740.664

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Jeisys Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=38633.971/964385.610
=4.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jeisys Medical EBIT Related Terms

Thank you for viewing the detailed overview of Jeisys Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Jeisys Medical Business Description

Traded in Other Exchanges
N/A
Address
76 Eulji-ro, Jung-gu, Seoul, KOR, 04538
Jeisys Medical Inc is a medical device manufacturer that produces high-end products for plastic surgeons, dermatologists, physicians, and healthcare professionals. Some of its products include ULTRAcel Q+ system, Cellec V system, LIPOcel, AcGen, TRI-BEAM Premium, Edge ONE, and SmoothCool.

Jeisys Medical Headlines

No Headlines